The Cirrus-HCM trial is an open-label, four-week study evaluating the efficacy of two dosages (50 mg and 100 mg) of EDG-7500 in patients diagnosed with either obstructive or nonobstructive HCM. The ...

Alnylam Pharmaceuticals has landed a long-awaited FDA decision that expands use of its drug, Amvuttra, to the treatment of a type of cardiomyopathy that’s growing in prevalence. It’s the ...

The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

Dilated cardiomyopathy (DCM ... Early diagnosis and treatment of DCM is important.This review summarizes the known genetic causes of DCM. Published data on development of DCM amongst first ...

The FDA has approved a supplemental new drug application for the treatment of cardiomyopathy wild-type or hereditary ...

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...

Edgewise Therapeutics shares tumbled more than 20% Wednesday after the developmental drug company issued the results of its ...

Researchers at ACC's annual meeting reported first-in-human data from a clinical trial of TN-201 that suggested symptom improvement.

Robust Evidence of Disease Reversal in Severe Knock Out Mice Model Supports Tenaya’s Clinical Development Plan to Evaluate TN-201 as a Potential Treatment for Patients with MYBPC3-associated ...